In China , some ophthalmic new drug clinical trials used placebo as control .Two principles should be con-sidered in ethical review when placebo was used in these ophthalmic new drug clinical trials .Firstly, using placebo couldn't lead to irreversible or permanent vision loss .Secondly , there should be proper risk management in protocol and risk dis-closure in consent process .There are several important factors , including effects of standard treatment , risks of using pla-cebo, risk management in protocol and risk information in informed consent form , which should be used to assess the ra-tionality of placebo in ethical review .%一些研发中的眼科新药在进行临床试验时常常使用安慰剂作为对照。在眼科新药的临床试验中，使用安慰剂必须遵循两条原则，一是安慰剂的使用不能造成受试者视力不可逆或永久性的损害，二是研究者必须做好安慰剂的风险管控并将安慰剂的风险向受试者完全披露。对于安慰剂使用的伦理审查，应该从标准治疗的效果、安慰剂的风险、研究方案中风险的管理和知情同意书中风险的告知这几个方面进行综合评估。
展开▼
